About this trial
Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans. The capacity of subcutaneous (subQ) adipose tissue to expand and remodel is an important determinant of obesity-related health complications, and impaired expansion of subQ fat tissue is thought to contribute to the risk of diseases such as the Metabolic Syndrome (MetS) and type 2 diabetes mellitus (T2D). The objectives of the study are to evaluate the changes and mechanisms of (subQ) adipose tissue expandability that occur as a result of short-term weight gain and to investigate the effects on cardio-metabolic health outcomes. Findings from this study will provide new insight into the dynamics of adipose expansion and remodeling during changes in energy balance and how this may impact future fat tissue function and metabolic health.
Eligibility criteria
Qualifiers
Men and pre-menopausal women
18-42 years of age
BMI 23-35 kg/m2 (± 0.5 will be accepted)
Are willing to drink deuterium-labeled water (2H2O) for 8 weeks
Disqualifiers
Unstable weight in the last 3 months (± ~5% weight change)
Diagnosis of Type 1 or 2 diabetes or a fasting blood glucose > 110 mg/dL
Average screening blood pressure > 140/90 mmHg
Diagnosis of major organ disease (e.g. heart, kidney, lung, thyroid, liver disease) or abnormal liver enzymes that are, in the opinion of the MI, clinically significant and represent a problem for study inclusion.
Trial design
Treatments tested in this trial
- Control
- Overfeeding
Treatment groups
Sponsors and collaborators
Pennington Biomedical Research Center
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator